-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) issued an announcement to announce pre-clinical data on HMPL-A830 at the EORTC-NCI-AACR International Conference on Molecular Targeting and Cancer Treatment to be held in Barcelona, Spain from November 18 to 20, 2026. HMPL-A830 is the world's first (first-in-class) antibody-targeted conjugation drug (ATTC) candidate. It consists of a highly selective and potent KRAS small molecule inhibitor as the payload and conjugates it with an anti-epidermal growth factor receptor (EGFR) antibody.
Share
Listen to the news
Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) issued an announcement to announce pre-clinical data on HMPL-A830 at the EORTC-NCI-AACR International Conference on Molecular Targeting and Cancer Treatment to be held in Barcelona, Spain from November 18 to 20, 2026. HMPL-A830 is the world's first (first-in-class) antibody-targeted conjugation drug (ATTC) candidate. It consists of a highly selective and potent KRAS small molecule inhibitor as the payload and conjugates it with an anti-epidermal growth factor receptor (EGFR) antibody.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending